Christopher Hulme, PhD

Associate Professor of Pharmacology and Toxiclogy; Associate Professor of Organic and Medicinal Chemistry
Director, Southwest Comprehensive Center for Drug Discovery and Development, University of Arizona
Phone Number: 
(520) 626-5322
(520) 626-2466

Internal Contact Information

UACC Organizational Unit: 
Professional Bio: 

Dr. Hulme has built and run several high-throughput medicinal chemistry organizations in industry and transitioned to an academic role in late 2007.  He has managed portfolios of targets spanning the value chain in drug discovery from hit generation to progression of molecules into man and as such managed teams that produced early development candidates for PDEIV (Rhone-Poulenc Rorer) and VR-1 (Amgen).  In total, it is estimated that 60+ targets of interest have passed through his organizations, spanning a multitude of therapeutic areas that include oncology, metabolic disorders, inflammation, pain, and neurodegeneration.

As Director of BIO5 Medicinal Chemistry, Dr. Hulme has the resources and extensive infrastructure in place to initiate and significantly progress the translational campaign. More specifically, CNS projects previously falling under his jurisdiction include the development of inhibitors of JNK-3 for stroke (Amgen), MCHr for obesity (Amgen), Pyk-2 for the treatment of brain gliomas (University of Arizona) and BACE for Alzheimer’s (Lilly). A significant number of other kinases were also part of prior industrial portfolios he ran, including JNK-1, PKB, Aurora A/B and Plk-1, and preliminary collaborations at the University of Arizona and Yale include targeting Plk-4, ROCK and aPKC. Indeed, the Phe is well versed in addressing the need for molecular pre-requisite physico-chemical properties that enable passive BBB penetration and minimization of residence time in the BBB lipid bi-layer to dial out potential pGP efflux liabilities.

Dr. Hulme has been involved in kinase research for ~ 20 years, being a co-author on one of the very early medicinal chemistry reviews in the field. The DYRK1A collaboration with Dr. Travis Dunckley has been active for more than three years although needs sustained funding to build on the significant progress to date. Recent reviews by the collaborators detail the state-of-art relevance of the target and current inhibitor design, and emerging indications for Glioblastoma are being investigated. In short, he is extremely qualified to pursue members of the kinase target-family in the neurodegeneration field and this is supplemented by his national/international reputation in high-throughput medicinal chemistry and file enhancement arenas.

Research Information

Research Program: 
Therapeutic Development
Member Status: 
Research Member
Year of Membership Acceptance: 
University of Arizona
College of Pharmacy
Selected Publications: